Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Gary105 who wrote (469)	2/16/2010 6:32:28 PM
From: Dwayne Hines	Respond to of 534

The real interesting part is it looks like they are going to try and use the stuff on humans.

To: Gary105 who wrote (469)	2/22/2010 4:20:54 PM
From: Dwayne Hines	Respond to of 534

More good news for BJCT - 12:07 PM ET 2/22/10 \| BusinessWire Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI). The vaccine will be delivered to healthy volunteers by ZetaJet(R), a needle-free injection system (Bioject Medical Technologies Inc.) in combination with the intradermal electroporation system, Derma Vax(TM) (Cyto Pulse). The study will be sponsored by SMI and conducted at Sodersjukhuset, KI, by Principal Investigator Bo Hejdeman, M.D., Ph.D. The multivalent HIV vaccine was developed jointly by SMI and KI. The combination of intradermal injection by ZetaJet(R) and electroporation by Derma Vax(TM) is thought to potentiate and broaden the response of the vaccine. Clinical Investigator and Professor of Dermatovenerology, Eric Sandstrom, M.D., Ph.D. says: "Our studies have shown that low dose (1mg) intradermal Bioject DNA injections induce stronger and broader priming to HIV antigens than 'standard' (4mg) intramuscular priming. Dermal electroporation of HIV/DNA may further increase this effect." Britta Wahren, M.D., Ph.D., Professor in Clinical Virology at KI/SMI and responsible for the HIV vaccine constructs, says: "We expect that this type of delivery for genetic vaccines will strongly enhance the effect of the immunogen. It is likely that the combined delivery of vaccine genes by both the ZetaJet and electroporation can lead to a lower effective dose of vaccine DNA." The Derma Vax(TM) delivery system is designed to be safe, effective and highly tolerable for the patient. "We are optimistic the treatment will be effective and therefore have signed a letter of intent to participate in a follow-up Phase II trial in Tanzania and Mozambique," said Derin Walters, Cyto Pulse CEO.